Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock.
This will be a retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock. The two cohorts will be septic shock patients that were: 1) not on either a chronic β-blocker or angiotensin-converting-enzyme inhibitor (ACE inhibitor) or 2) on a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No chronic antihypertensives | Not on either a chronic β-blocker or ACE-Inhibitor | ||
| Chronic antihypertensives | On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative percent (%) of patients with new onset atrial fibrillation at 48 hours | New onset atrial fibrillation defined as atrial fibrillation not present on admission to MICU | 48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Heart rate > 100 | Total number of times with heart rate greater than 100 in 48 hours. | 48 hours |
| New onset of other arrhythmias | Total onset of other arrhythmias not present on admission. Examples include, ventricular fibrillation, ventricular tachycardia, heart blocks, etc |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult, non pregnant medical intensive care (MICU) patient's with septic shock
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joshua DeMott, Pharm.D. | Rush University Medical Center | Principal Investigator |
| Ishaq Lat, Pharm.D. | Rush University Medical Center | Principal Investigator |
| Gourang Patel, Pharm.D. | Rush University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rush Univeristy Medical Center | Chicago | Illinois | 60612 | United States |
To be determined
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
| 48 hours |
| Peak lactate | Peak lactate level during the first 48 hours of admission | 48 hours |
| Duration of mechanical ventilation | During admission |
| In hospital mortality | During admission |
| 28 day mortality | 28 days after discharge |
| 90 day mortality | 90 days after discharge |
| New onset atrial fibrillation for patients on other antiarrhythmics | Antiarrhythmic agents that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. Will include any single or combination of class I, II, III, IV antiarrhythmic agents | 24 and 48 hours |
| Cumulative percent (%) of patients with new onset atrial fibrillation at 24 hours | 24 hours |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D012769 | Shock |